Thrombo-inflammatory endothelial signatures in JAK2-mutated myeloproliferative neoplasms

This study demonstrates that endothelial cells derived from patients with JAK2-mutated myeloproliferative neoplasms exhibit a non-clonal, thrombo-inflammatory phenotype characterized by enhanced procoagulant activity and specific transcriptomic dysregulation, suggesting that a primed endothelium cooperates with clonal hematopoiesis to drive the elevated thrombotic risk in these disorders.

The Gist

The Big Picture: A Traffic Jam in the Bloodstream

Imagine your body's blood vessels as a massive, high-speed highway system. The endothelium is the smooth, non-stick pavement lining these roads. Under normal conditions, cars (blood cells) glide over it effortlessly, and traffic flows smoothly.

Myeloproliferative Neoplasms (MPN) are a group of blood cancers where the bone marrow acts like a factory that goes into overdrive, pumping out too many red blood cells, white blood cells, or platelets. This creates a "traffic jam" in the bloodstream. A major danger for these patients is thrombosis—clots forming on the highway, causing heart attacks, strokes, or blockages in the liver and spleen.

For a long time, scientists thought the problem was entirely caused by the "cars" (the blood cells) being too aggressive or sticky. But this new study asks a different question: Is the "pavement" itself damaged?

The Detective Work: Using "Seedlings" to Study the Road

Studying the actual lining of blood vessels inside a living person is like trying to scrape a tiny patch of asphalt off a moving highway without crashing the car. It's incredibly difficult and dangerous.

To solve this, the researchers used a clever workaround. They harvested Endothelial Colony-Forming Cells (ECFCs). Think of these as "seeds" or "seedlings" that circulate in the blood. When you plant them in a petri dish (a test tube), they grow into a full patch of pavement (endothelial cells). This allowed the team to grow a "mini-highway" in the lab from patients with MPN and compare it to healthy people.

Key Findings: The Pavement is "Primed" for Disaster

The study revealed three major discoveries:

1. The Pavement is "Sticky" and "Angry"
In healthy people, the road surface is smooth. In MPN patients, the researchers found that the "pavement" was covered in sticky tape and warning flares.

• The Analogy: Imagine the road surface is covered in Velcro (sticky) and flashing red lights (inflammation).
• The Science: The cells from MPN patients released huge amounts of von Willebrand factor (a glue that helps blood clot) and P-selectin (a magnet that grabs passing blood cells). This makes it much easier for clots to form, even if the blood cells themselves aren't doing anything wrong.

2. The "Seeds" are Growing Faster
The researchers noticed that they could grow these "pavement seeds" much more easily and in greater numbers from MPN patients than from healthy people.

• The Analogy: It's as if the MPN patients' bodies are constantly shouting, "We need more road repair!" and sending out more repair crews (seeds) than usual.
• The Meaning: This suggests the body senses the blood vessels are under attack and is trying to regenerate them, but the new "road" is being built in a chaotic, inflammatory environment.

3. The "Blueprint" is Corrupted, But the "Builder" is Innocent
This is the most surprising part. Scientists wondered: Did the cancer mutation (JAK2) jump into the road pavement itself, turning the road into a mutant, dangerous surface?

• The Discovery: They checked the DNA of the "pavement seeds." No mutation was found. The road builders are innocent.
• The Analogy: Imagine a construction crew building a road. The crew members (the cells) are normal and healthy. However, the foreman (the blood environment filled with inflammatory signals from the cancer) is screaming orders to "Make the road sticky! Add more glue!"
• The Conclusion: The road isn't broken because of a genetic defect in the road itself; it's broken because the environment around it is toxic and inflammatory. The "normal" road cells are being forced to act like a "bad" road.

The "Blueprint" (Genetic Analysis)

The researchers took a snapshot of the genes (the instruction manual) inside these cells.

• They found 289 different instructions being followed differently in MPN patients compared to healthy people.
• The instructions that were turned "ON" were all about clotting, inflammation, and repairing the road.
• The instructions that were turned "OFF" were about keeping the road smooth and calm.
• Essentially, the cells have been reprogrammed to be in a state of "high alert," ready to clot at a moment's notice.

Why This Matters

This study changes how we view the danger of MPN.

• Old View: The blood cells are the bad guys; the blood vessels are just innocent bystanders.
• New View: The blood vessels are active participants. Even though they don't have the cancer mutation, they are being "hijacked" by the inflammatory environment to become sticky and dangerous.

The Takeaway:
Treating MPN patients might require more than just slowing down the overactive blood cell factory. We may also need to "calm down" the road pavement itself, reducing the inflammation that turns a smooth highway into a sticky trap for clots.

Summary in One Sentence

This study shows that in blood cancer patients, the blood vessel walls aren't genetically mutated, but they are being forced by the surrounding inflammation to become sticky, angry, and prone to causing dangerous clots, acting like a highway covered in glue and warning flares.

Technical Summary

1. Problem Statement

Classical Myeloproliferative Neoplasms (MPNs), including Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF), are driven by clonal hematopoiesis (often via the JAK2 V617F mutation) and are characterized by a significantly elevated risk of thromboembolic events (TEs). While the role of hyperreactive platelets and leukocytes in MPN thrombosis is well-established, the contribution of the vascular endothelium remains poorly defined.

Key unresolved questions include:

• Does the vascular endothelium in MPN patients exhibit intrinsic dysfunction?
• Is the endothelial dysfunction driven by the acquisition of the JAK2 V617F mutation within endothelial cells (clonal origin) or by a reactive, non-clonal response to the inflammatory MPN milieu?
• What are the specific transcriptomic and functional signatures of MPN-associated endothelial cells?

2. Methodology

The study utilized Endothelial Colony-Forming Cells (ECFCs) derived from peripheral blood as a surrogate for the vascular endothelium.

• Cohort: 7 patients with JAK2 V617F-mutated MPN (3 ET, 3 PV, 1 PMF) and 13 healthy controls.
• Cell Culture: Peripheral Blood Mononuclear Cells (PBMCs) were cultured to isolate ECFCs. Cells were phenotyped as bona fide endothelial cells (CD45 negative, CD144/PECAM1 positive, vWF positive with Weibel-Palade bodies).
• Genetic Analysis: Quantitative PCR (qPCR) was performed on all ECFC colonies to detect the JAK2 V617F mutation (limit of detection <0.01% VAF).
• Functional Assays:
  • Thrombo-inflammatory markers: ELISA for von Willebrand factor (vWF) content and release; Flow cytometry for P-selectin surface expression.
  • Procoagulant activity: Endothelial-dependent Factor Xa generation assay following LPS stimulation.
  • Proliferation: MTT assay to assess cell growth rates.
• Transcriptomics: Bulk RNA sequencing (RNA-seq) was performed on 10 MPN and 5 control ECFC colonies.
  • Analysis Pipeline: Reads aligned to GRCh38 (HISAT2), quantified (StringTie2/Salmon), and differential expression analyzed (DESeq2).
  • Benchmarking: ECFC transcriptomes were compared against a public Human Umbilical Vein Endothelial Cell (HUVEC) reference dataset to confirm endothelial identity and assess "HUVEC-likeness."
  • Pathway Analysis: Gene Ontology (GO) enrichment via Enrichr and Metascape; module scoring for NF-κB and inflammatory pathways.

3. Key Contributions

• Non-Clonal Origin of Endothelial Dysfunction: The study definitively demonstrates that ECFCs derived from MPN patients do not harbor the JAK2 V617F mutation, supporting a model where endothelial dysfunction is a secondary, reactive phenomenon rather than a clonal expansion of mutated endothelial cells.
• Integrated Phenotypic-Transcriptomic Profile: This is one of the first studies to combine functional thrombo-inflammatory assays with deep transcriptomic profiling specifically in patient-derived ECFCs, moving beyond descriptive studies to mechanistic insights.
• Validation of ECFCs as a Model: The study confirms that ECFCs retain a robust endothelial transcriptional program (high correlation with HUVECs) even in the disease state, validating their use as a model for studying MPN vascular biology.

4. Key Results

A. Enhanced Regenerative Capacity

• Yield: ECFCs were isolated more frequently and in greater numbers from MPN patients (6/7 patients) compared to controls (5/13 controls).
• Colony Count: MPN patients yielded a significantly higher mean number of colonies (7 vs. 1.3, p=0.0033).
• Proliferation: Despite higher colony numbers, the proliferation rate (MTT assay) and time to colony appearance were similar between groups, suggesting increased mobilization of endothelial progenitors rather than intrinsic hyper-proliferation.

B. Thrombo-Inflammatory Phenotype

• vWF and P-Selectin: MPN ECFCs showed significantly elevated vWF content (5260 vs. 1160 AU, p=0.004) and increased vWF release. P-selectin surface expression was also significantly higher (MFI 358 vs. 190, p=0.008).
• Procoagulant Activity: MPN ECFCs demonstrated significantly elevated LPS-stimulated, tissue factor-dependent Factor Xa generation, indicating a procoagulant state.
• Heterogeneity: Significant intra-subject heterogeneity was observed in marker expression, suggesting dynamic, locally regulated activation.

C. Transcriptomic Signatures

• Differentially Expressed Genes (DEGs): 289 genes were differentially expressed (289 DEGs; adj. p < 0.05, FC > 1.5).
• Endothelial Identity: ECFCs showed high concordance with HUVEC references (Pearson r > 0.96), confirming they retained endothelial identity despite disease-associated changes.
• Pathway Enrichment: Upregulated pathways included:
  • Blood coagulation and platelet activation regulation.
  • Vascular permeability and extracellular matrix (ECM) organization.
  • Angiogenesis and plasminogen regulation.
  • Specific upregulation of SELE (E-selectin), NFKBIA (IκBα), and VWF.
• NF-κB Priming: While specific inflammatory genes (SELE, NFKBIA) were upregulated, global NF-κB feedback module scores did not show a uniform baseline shift, suggesting a state of selective inflammatory priming rather than full constitutive activation.

5. Significance and Conclusion

The study proposes a "Two-Hit" model for thrombosis in MPN:

1. Clonal Hematopoiesis: The JAK2 V617F mutation drives the production of hyperreactive blood cells (platelets/leukocytes).
2. Reactive Endothelial Priming: The endothelium, though non-clonal (lacking the mutation), exists in a "primed" thrombo-inflammatory state due to chronic exposure to the MPN milieu (cytokines, activated blood cells, procoagulant factors).

Clinical Implications:

• The endothelium is an active participant in MPN pathobiology, not a passive bystander.
• Therapeutic strategies targeting endothelial activation (e.g., anti-adhesion molecules, anti-inflammatory agents) alongside cytoreductive therapy may be necessary to fully mitigate thrombotic risk in MPN patients.
• The findings resolve the debate regarding the clonal nature of MPN endothelium, clarifying that ECFCs represent a reactive, non-mutated population that nonetheless drives vascular complications.

Limitations:

• Modest sample size (7 MPN patients).
• Bulk RNA-seq masks single-cell heterogeneity.
• ECFCs may not perfectly replicate all vascular beds (e.g., splanchnic or microvasculature) relevant to MPN thrombosis.